Skip to content
MARKETS / NASDAQ / RXST
NASDAQ · OPHTHALMIC GOODS · MID CAP

RxSight, Inc. RXST

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$134.5M
▼ 3.9% YoY
$-38.9M
$-19.3M
In brief

What this company does

RxSight, Inc. is a commercial-stage medical technology company that provides customized vision to patients following cataract surgery. Its RxSight system comprises the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, along with related accessories. As of December 31, 2025, the company had 461 full-time employees. The company manufactures, assembles, tests and ships its LAL and LDD products at a campus of five facilities in Aliso Viejo, California, totaling approximately 150,000 square feet. As of December 31, 2025, it had an installed base of 1,134 LDDs in ophthalmology practices, and surgeons had implanted approximately 300,000 LALs since its inception. Its RxSight system has regulatory approval in the U.S., Europe, Canada, Mexico, Singapore, Australia and South Korea. In the U.S., it primarily sells its LAL products to ambulatory surgical centers, and occasionally to hospitals. The company was incorporated in California on March 5, 1997 as Calhoun Vision, Inc., changed its name to RxSight, Inc. in October 2016, and reincorporated in Delaware on July 6, 2021.

Written from the business description in RxSight, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 134.5M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 134.5 · Net income -38.9
50.0M100.0M-25.0M-50.0M202020212022202320242025
Compound annual growth
+40.0%
+55.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +55.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -35.8% · Net -29.0%
50%100%150%-100%-200%202020212022202320242025
ROE
FY2025 · ROE -14.0%
-20%-40%202020212022202320242025

Each USD of equity lost 14 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.3
-25.0M-50.0M202020212022202320242025

Total assetsUSD 311.8M
EquityUSD 275.7M
CashUSD 19.9M
Current ratio10.95×

Equity funds 88% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.10.10.10.00.00.0
Operating income $B−0.0−0.0−0.1−0.1−0.1−0.0
EBITDA $B−0.0−0.0−0.0−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.1−0.00.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.0−0.0
EPS, diluted $−0.95−0.71−1.41−2.41−3.570.15
Dividend / sh $······
Payout %······
ROE %−14.0−12.4−38.8−58.5··
Shares out B0.040.040.040.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOphthalmic Goods
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2020

Share this section

Download image